Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Product of manufacture and method for treating, ameliorating or preventing coronavirus infection

A product and therapeutic technology, applied in the field of infectious diseases, which can solve the problems of difficult to use antiviral agents, no single drug regimen has been found for coronavirus infection, and coronavirus anti-infective agents cannot cure infection, etc.

Pending Publication Date: 2022-04-12
TOPELIA AUSTRALIA PTY LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Coronavirus infections have previously caused SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) and are particularly difficult to treat with antiviral agents, and single-drug regimens have not been found to be effective against the current coronavirus infection (2019-nCoV)
No known coronavirus anti-infective agent used alone or alone can cure infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Product of manufacture and method for treating, ameliorating or preventing coronavirus infection
  • Product of manufacture and method for treating, ameliorating or preventing coronavirus infection
  • Product of manufacture and method for treating, ameliorating or preventing coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0393] Example 1: Exemplary Treatment Protocol

[0394] A 42-year-old (y) female patient was first treated with oseltamivir (or TAMIFLU TM ) for treatment. She was treated for 4 days, but then developed fever, cough, aches and some difficulty breathing, and her blood results were positive for the COVID-19 virus.

[0395] As the patient remains positive for the 2019-nCoV virus, lopinavir and ritonavir or KALETRA are now TM , ALTERA TM 、ALUVIA TM , KALMELTREX, LOPIMUNE TM or LOPINAVIR TM Treatment was added to oseltamivir therapy, and within 48 hours, her blood test turned negative for the coronavirus.

[0396] The patient was very sick, reaching a stage of dyspnea and having trouble walking, and was expected to die if not for this new drug combination. The combination of drugs as provided herein can rapidly clear the coronavirus from a patient's blood, thereby terminating or significantly ameliorating an otherwise life-threatening disease.

Embodiment 2

[0397] Example 2: Exemplary Treatment Protocol

[0398] A 47-year-old male returning from travel presented with draggles and muscle pain and a temperature of 37.5°C. He was tested for the coronavirus and found positive for COVID-19 on a swab test. He was started on chloroquine 250 mg twice daily, lopinavir 200 mg bid, ritenovir 50 mg bid, and oseltamivir 75 mg bid (optionally, TAMIFLU TM )The combination.

[0399] His symptoms further improved within three days, and a swab test on the sixth day was negative. The muscle pain also disappeared and he felt fine and was able to be discharged home on the seventh day.

Embodiment 3

[0400] Example 3: Exemplary Treatment Protocol

[0401] A group of elderly travelers boarded a cruise ship, and many on board were exposed to the coronavirus, COVID-19, which was being tested for. This group was administered an inhalant comprising two inhalation or aerosol doses or 125 mg of chloroquine twice daily as prophylaxis / treatment. No one was infected with the COVID-19 coronavirus and tested negative for the virus when they returned home from the cruise.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are therapeutic agents, combination therapies, and methods for the treatment of coronavirus infections and related diseases, particularly COVID-19. The therapeutic agents provided include oseltamivir, lopinavir, ritonavir, chloroquine or hydroxychloroquine, azithromycin, clarithromycin, doxycycline, ivermectin, and combinations thereof.

Description

[0001] This Patent Cooperation Treaty (PCT) International Application claims the benefit of priority to U.S. Utility Application Serial Number (USSN) 17 / 116,942 filed on December 09, 2020 and filed on March 24, 2020 Continuation-in-Part (“CIP”) of U.S. Patent Application Serial No. (USSN) 16 / 828,891 (now pending) filed and claiming priority under 35 U.S.C. §120, which was filed under 35 U.S.C. e) Claims USSN 62 / 971,803 filed February 7, 2020; USSN 62 / 972,486 filed February 10, 2020; USSN 62 / 988,852 filed March 12, 2020; USSN 62 / 990,283, filed on the 16th; and USSN 62 / 992,137, filed on March 19, 2020, and this application also filed on May 4, 2020 pursuant to 35 U.S.C. §119(e) USSN 63 / 019,883; USSN 63 / 060,461, filed August 03, 2020; and priority of USSN 63 / 109,214, filed November 3, 2020. The foregoing applications are hereby expressly incorporated by reference in their entirety and for all purposes. technical field [0002] The present invention relates generally to infectio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/4706A61K31/4409A61K31/215A61K31/427A61K31/675A61K31/165A61K31/375A61K31/495A61K31/593A61K31/65A61K33/30A61P31/14
CPCA61K31/65A61K2300/00A61K31/4409A61K31/7048A61K31/165A61K31/375A61K31/675A61K31/4706A61K31/593A61K31/426A61K31/495A61K33/30A61K31/215A61P31/14A61K9/0019A61K9/0078A61K31/513A61K31/427A61K31/706A61K31/35A61K31/7052A61K31/47A61K9/14A61K9/0053A61K9/0073A61K9/20A61M15/0068A61K9/0075A61K31/137A61K31/436A61K38/21A61K39/215A61K39/3955A61M15/0045A61M15/009A61M15/08A61M2202/064C12N7/00C12N2770/20034
Inventor 托马斯·朱利叶斯·波洛迪
Owner TOPELIA AUSTRALIA PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com